-
Sobi’s Anakinra (Kineret) Prioritized for Review in China for FMF Treatment
•
The Center for Drug Evaluation (CDE) website indicates that Swedish Orphan Biovitrum AB’s (Sobi; BMV: SOBIN) market filing for its anakinra (trade name: Kineret) has been prioritized for review. The drug is indicated for autoinflammatory periodic fever syndrome (familial Mediterranean fever – FMF) in adults, adolescents, children, and infants eight…
-
Arctic Vision Enrolls First Patient in ARVN003 Phase III Trial for Presbyopia
•
China-based ophthalmic therapies developer Arctic Vision announced the first patient enrollment in a Phase III clinical study for its ARVN003, a proprietary pilocarpine formulation leveraging its micro-dosing platform Optejet. The study aims to evaluate the efficacy and safety of ARVN003 in temporarily improving vision in adults with presbyopia (long-sightedness) in…
-
WuXi Biologics’ MFG14 Facility Approved for Microbial Product Manufacturing
•
China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) announced that its MFG14 facility in Hangzhou has been released for manufacturing microbial-derived products. The facility has been successfully performing Chemistry, Manufacturing, and Controls (CMC) projects for multiple clients since early 2022, demonstrating the company’s capability to provide…
-
JW Therapeutics Initiates Phase I Study of JWATM204 for Hepatocellular Carcinoma
•
China-based JW Therapeutics (HKG: 2126) announced the initiation of a Phase I clinical study for its JWATM204 in patients with advanced hepatocellular carcinoma (HCC). This first-in-human study aims to evaluate the safety, tolerability, dose-limiting toxicity, and pharmacokinetic profile of JWATM204 in adult subjects with advanced HCC. It will also explore…
-
GenScript Biotech’s ProBio Subsidiary Receives USD 37.25M Investment from Zhenjiang Gaoxin
•
Hong Kong-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) announced that Zhenjiang Gaoxin Venture Capital Co., Ltd, a wholly-owned subsidiary of state-owned Jiangsu Hanrui Investment Holdings Co., Ltd, is set to acquire 57.31 million Series B preferred ProBio shares for a consideration of USD 37.25 million. The proceeds…
-
Zhiyi Bio Raises RMB 100M in Series B++ Round for LBP Pipeline Development
•
China-based leading live biotherapeutics (LBP) company Guangzhou Zhiyi Biotechnology Co., Ltd has recently raised RMB 100 million (USD 14.93 million) in a Series B++ financing round. The round was led by SDIC Venture Capital, Guangzhou Development District Investment Group, and Guangzhou Helichuangxing Group Co., Ltd. The proceeds will be used…
-
Brii Biosciences Exercises Option for VIR-3434 in Greater China
•
China-based Brii Biosciences Limited (HKG: 2137) announced the exercise of its option to acquire exclusive development and commercialization rights for VIR-3434 (BRII-877) in Greater China as part of its broader collaboration with Vir Biotechnology, Inc. (NASDAQ: VIR). Drug ProfileVIR-3434, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody, is designed to block…
